48 – PK/PD in Phase 1 (S4E3)

OK, so you have this incredible idea for a groundbreaking
new drug, something that could be a total game
changer for a specific disease. But how do you
go from that initial spark to an actual safe
and effective treatment, something people can
actually take? Yeah, well, that's where the whole
intricate world of drug development comes in.
And today, We're going deep into a crucial stage,
those first human trials, phase one trials. That's
where a new drug is tested in humans for the
very first time. It's like stepping into completely
uncharted territory, right? You have this promising
drug candidate, but you need to figure out a
lot of things like. Is it safe? How does it actually
behave in the body? And does it even have a chance
of working? Exactly. And to navigate those initial
trials, scientists rely on this dynamic duo PK
and PD pharmacokinetics and pharmacodynamics.
OK, I'll admit those terms always sound a bit
intimidating to me. But they make sense once
you break them down, right? Oh, absolutely. Pharmacokinetics
PK is basically understanding what the body does
to the drug. It's like tracking the drug's journey
through the body, how it's absorbed, how it's
broken down, where it travels, and eventually
how it's eliminated. So it's like we're following
this drug molecule on a crazy obstacle course
through the body, seeing how it navigates every
hurdle. from absorption to excretion. That's
a great analogy. And while we're tracking that
adventure, pharmacodynamics, or PD, helps us
understand what the drug does to the body. That's
where we look at its effects on cells, tissues,
organs. Does it lower blood pressure? Does it
shrink a tumor? Does it reduce inflammation?
So PK is like mapping the journey, and PD is
assessing the impact at the destination. But
why study them together, especially in these
phase one trials? Well, it's all about finding
that sweet spot. We need to figure out a dose
that's both safe and effective. To do that, we
need to understand how the drug's journey, the
PK, influences its impact on the body, the PD.
Okay, that makes sense. Can we maybe walk through
an example to see how this all works? Sure, let's
say we're looking at a new blood pressure medication
in phase one. On the PK side, scientists will
be looking at things like how quickly it's absorbed
into the blood, how long it stays there, and
how efficiently it's metabolized by the liver,
basically mapping its concentration over time.
So tracking the rise and fall of the drug in
the body. But how do they connect that to its
actual effect on blood pressure? That's where
PD comes in. Exactly. Alongside the PK measurements,
researchers are monitoring the participants'
blood pressure at different time points after
they receive the drug, looking for a correlation
between the drug's concentration and any reduction
in blood pressure. So if the concentration is
high, we should see a bigger drop in blood pressure,
and if it drops, the effect would lessen. It's
all about connecting the PK and PD dots. Precisely.
Analyzing both sets of data helps scientists
understand the relationship between the drug
exposure and the effect. This helps determine
the optimal dose for later trials. A dose that
actually works to lower blood pressure but also
minimizes side effects. That's like fine -tuning
an instrument, right? You adjust the dosage just
right to get the desired effect without going
overboard. But how do they even measure these
drug concentrations? We're talking about tiny
molecules in a very complex system. That's where
the incredible world of bioanalytical measures
comes in. And it all starts with something pretty
simple, blood samples. Blood samples. Seems like
those play a huge role in the whole process.
They really do. They're like snapshots in time
capturing the concentration of the drug at that
specific moment. Scientists use some really sophisticated
techniques to analyze those samples and figure
out exactly how much drug is there. So it's not
just looking at the blood itself. They're zooming
in to the molecular level. But what kind of tech
allows them to do that so precisely? One of the
most powerful tools is something called liquid
chromatography, coupled with tandem mass spectrometry.
It's a mouthful, so we just call it LC -MS -MS.
LC -MS -MS. Yeah. OK, that sounds pretty impressive.
I have to admit I need a bit of help visualizing
that. Think of it like a super high -tech sorting
machine separating those drug molecules from
all the other stuff in the blood sample. That's
liquid chromatography. It acts like a molecular
sieve, isolating the drug based on its unique
properties. It's like sifting through a haystack
to find the needle, but on a microscopic level.
Pretty amazing. Yeah. But once they have isolated
the molecules, how do they measure them? That's
where tandem mass spectrometry comes in. It lets
scientists measure the mass to charge ratio of
ions, which is like a molecular fingerprint for
each molecule. So they're identifying the drug
based on its unique weight and electrical charge.
Exactly. By combining those two techniques, they
pinpoint the amount of drug in the sample, even
in tiny amounts. Incredible. It's like a high
-stakes detective story, tracking down those
molecules and understanding how they affect our
health. But... All of this happens under some
pretty strict regulations, right? Absolutely.
Organizations like the FDA and the ICH have strict
guidelines for phase one trials. It's all about
the safety of the participants and making sure
the results are reliable. So it's not just about
the science. It's about making sure the science
is done responsibly and ethically. Exactly. These
organizations have guidelines covering everything
from how the drug is made, the qualifications
of the people running the trial, to how the data
is collected, analyzed, and reported. No stone
unturned. But why is data quality so crucial
at this early stage? Because the data from phase
one trials really sets the stage for everything
that comes after. If the data is bad or incomplete,
it could derail the whole process. So these regulations
are there to make sure the data is accurate,
transparent, and trustworthy. Makes sense. It's
also about protecting the people participating
in these trials. They're often the first humans
to ever receive this new drug, so their safety
and well -being are the top priority. And it's
not just blood pressure medications where PK
and PD come in. Imagine a potential new anti
-cancer drug entering phase one. Okay, so from
a chronic condition like hypertension to something
as complex as cancer, I imagine the balance between
safety and efficacy is even more crucial there.
Definitely. One of the biggest challenges with
cancer drugs is getting it to the tumor without
damaging healthy cells. It's like navigating
a minefield. You need that precise path to deliver
the therapy without any unwanted explosions.
So how do PK and PD help researchers chart that
course through this molecular minefield? Well,
on the PK side, we're talking about understanding
how well the drug gets into the tumor, how long
it stays there, and if it builds up anywhere
else in the body where it could cause side effects.
Basically mapping its distribution, making sure
it's hitting the target, and minimizing those
off -target effects. So like making sure it takes
the right exit off the highway and doesn't get
lost on some back road and cause trouble. Exactly.
But just getting to the tumor isn't enough. It
needs to actually work once it's there. That's
where PD comes in. Right. Just showing up isn't
enough. You gotta make an impact. Precisely.
PD studies for an anti -cancer drug might look
at things like, is it actually shrinking the
tumor, slowing its growth, or even killing cancer
cells? We're looking for evidence of a real impact
on the disease. Like sending in a spy. Yeah.
You need to confirm they've reached the target
and are carrying out their mission. It's fascinating
how PK and PD work together for that complete
picture. It's a really remarkable partnership,
and the insights from these Phase I trials are
so valuable for guiding the drug's future. We've
talked about blood pressure meds and cancer drugs.
Any other examples that highlight these PKPD
studies? Absolutely. Let's say we're developing
a new antiviral drug for a new viral infection,
something like, oh, I don't know, a global pandemic
maybe. OK, that scenario hits a little too close
to home these days. Yeah. But I'm curious how
PK and PD fit in there. Well, with an antiviral
drug, PK studies would focus on things like how
it's absorbed, distributed throughout the body,
if it reaches the target cells where the virus
is replicating and how long it stays active.
Similar to the cancer drug example, making sure
it gets where it needs to go and stays there
long enough. Exactly. But with antivirals, you're
also looking at how it interacts with the virus
itself. Does it block the virus from entering
cells? Does it stop it from replicating? Those
are PD questions. So not just tracking the drug,
but understanding how it engages with the enemy,
so to speak. Right. The PD studies would measure
things like how well it stops viral replication,
reduces viral load, and ultimately helps the
patient recover. Connecting the drug's journey
through the body, PK, with its impact on the
virus PD. Exactly. Am I carefully analyzing both
PK and PD data scientists can start to see how
effective the drug is, optimize the dose, and
identify any potential safety issues? You know,
it's easy to think of drug development as this
straightforward process. But it sounds like there's
a lot of back and forth, a lot of fine tuning
going on. Absolutely. It's iterative with insights
from one stage informing the next. And PK PD
studies are a big part of shaping that journey.
OK. So we've seen some examples of PK PD studies
in action. But I'm still curious about those
bioanalytical techniques you mentioned. How do
they actually measure those tiny drug molecules?
That's where the science gets really exciting.
Remember those blood samples we talked about?
Yes, they seem to be a key player in all of this.
They are... Sinuses use them to measure the drug
concentration in the plasma. They use some pretty
incredible techniques like that liquid chromatography
coupled with tandem mass spectrometry LC -MS
-MS. LC -MS -MS, right? That high -tech sorting
machine and molecular fingerprint analyzer still
sounds pretty futuristic to me. It might sound
like sci -fi, but it's a real and powerful tool.
It helps us understand how drugs work in the
body. To simplify the liquid chromatography part
is a separation system. Imagine a microscopic
racetrack where molecules compete each with their
own speed and agility. So they're separating
the drug from everything else in the blood based
on how it moves through this molecular obstacle
course. Exactly, like sorting candies by size
and shape. Once they've isolated the drug molecules,
tandem mass spectrometry comes in. It measures
the mass to charge ratio of ions, which is like
a fingerprint for each molecule. So each molecule
has its own ID card. You got it. Combining those
two techniques lets scientists accurately identify
and quantify the drug in the sample, even if
there's just a tiny bit. It's like they're doing
a microscopic forensic investigation with cutting
-edge technology, tracking down those molecules
and understanding their every move. But this
all happens under strict regulations, I assume.
Of course, organizations like the FDA and the
ICH have those strict guidelines for phase one
trials. It's all about protecting the participants
and ensuring data quality and reliability. Think
of it as a detailed rule book for the whole trial.
So it's not just the science, but making sure
it's done responsibly and ethically. What do
these regulations cover? A lot of things from
how the drug is made, the qualifications of the
people running the trial, to how the data is
collected, analyzed, and reported. Wow, they're
not messing around. Yeah. But why is data quality
so crucial in these early trials? Because the
data from phase one really lays the foundation
for the drug's entire future. If the data is
unreliable or incomplete, it could derail the
whole thing. So these regulations are about making
sure the data is accurate, transparent, and trustworthy.
That makes sense. And it's about protecting the
people in the trials. They're often the first
humans to receive this drug, so their safety
and well -being are the absolute priority. It's
amazing to think about all the detail and precision
in these early trials. It's like building a house
brick by brick, making sure it's solid before
anyone even steps inside. That's a great way
to put it. And just like building a house, there
are always new ways to innovate and improve the
process. You know, we've been talking about measuring
drug levels in the blood. But what if we could
track a drug's journey through the body in real
time without even having to draw blood? Wait,
really? Is that even possible? Sounds like something
out of Star Trek. It might sound futuristic,
but it's getting closer every day. There are
new technologies being developed that could let
us monitor a drug's movement without being invasive.
Imagine tiny little biosensors implanted in the
body that could continuously measure drug concentrations
in specific tissues or organs. So instead of
relying on those snapshots from blood samples,
we'd have this constant stream of data showing
us exactly where the drug is and how much is
there, like a GPS tracker for drug molecules.
Precisely. That kind of real -time monitoring
could completely change how we understand PKPD
relationships. We could see the drug interacting
with its target in real time adjust doses much
more more precisely, and even maybe personalized
treatments based on how each person responds.
This is incredible. Yeah. How far off are we
from actually using this kind of technology in
drug development? There are still challenges
to overcome, but the progress is really exciting.
Scientists are working on making these biosensors
sensitive, reliable, and biocompatible, meaning
they won't harm the body. And with all the advances
in nanotechnology and wireless communication,
the idea of real -time drug monitoring is becoming
more and more realistic. It's amazing how technology
is changing how we understand drug development.
It feels like we're constantly pushing the boundaries
of what's possible. It really is an exciting
time to be in this field. I think these advances
will eventually lead to treatments that are safer,
more effective, and more personalized for patients.
Thanks to this deep dive, I have a whole new
appreciation for the world of drug development.
From those first steps in the lab to these crucial
first human trials, it's an amazing journey.
I agree. It all boils down to this collaboration
between scientists, clinicians, regulatory bodies,
and of course, the brave volunteers who participate
in these trials. They're the unsung heroes paving
the way for new treatments. It all begins with
that simple question. How do we turn a scientific
idea into a medicine that can help people? And
that question keeps driving innovation and discovery
in this field. Well, on that note of scientific
wonder and the potential for new treatments,
we'll wrap up our deep dive into the world of
phase one trials and PKPD studies. We hope you
enjoyed the journey as much as we did. It's been
fascinating. And to our listeners, stay curious.
Keep asking those questions and never stop exploring
the world around you. Until next time.